PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
// Tao Lu 2, * , Yanmei Zou 1, * , Guogang Xu 3 , Jane A. Potter 4 , Garry L. Taylor 4 , Qiuhong Duan 2 , Qin Yang 5 , Huihua Xiong 1 , Hong Qiu 1 , Dawei Ye 1 , Peng Zhang 1 , Shiying Yu 1 , Xianglin Yuan 1 , Feng Zhu 2 , Yihua Wang 6 , Hua Xiong 1 1 Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, 430030, China 2 Department of Biochemistry and molecular biology, School of Basic Medicine, Huazhong University of Science and Technology, Wuhan, 430030, China 3 Nanlou Respiratory Department, Chinese PLA General Hospital, Beijing, 10083, China 4 BioMedical Research Complex, University of St Andrews, St Andrews, KY16 9ST, UK 5 Department of Pathology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, 430030, China 6 Biological Sciences, Faculty of Natural and Environmental Sciences, University of Southampton, Southampton SO17 1BJ, UK * These authors have contributed equally to this work Correspondence to: Hua Xiong, email: cnhxiong@163.com Keywords: PRIMA-1 Met , MEK, p53, colorectal cancer, tumorigenesis Received: October 17, 2015 Accepted: October 10, 2016 Published: October 27, 2016 ABSTRACT PRIMA-1 Met is the methylated PRIMA-1 (p53 reactivation and induction of massive apoptosis) and could restore tumor suppressor function of mutant p53 and induce p53 dependent apoptosis in cancer cells harboring mutant p53. However, p53 independent activity of PRIMA-1 Met remains elusive. Here we reported that PRIMA-1 Met attenuated colorectal cancer cell growth irrespective of p53 status. Kinase profiling revealed that mitogen-activated or extracellular signal-related protein kinase (MEK) might be a potential target of PRIMA-1 Met . Pull-down binding and ATP competitive assay showed that PRIMA-1 Met directly bound MEK in vitro and in cells. Furthermore, the direct binding sites of PRIMA-1 Met were explored by using a computational docking model. Treatment of colorectal cancer cells with PRIMA-1 Met inhibited p53-independent phosphorylation of MEK, which in turn impaired anchorage-independent cell growth in vitro. Moreover, PRIMA-1 Met suppressed colorectal cancer growth in xenograft mouse model by inhibiting MEK1 activity. Taken together, our findings demonstrate a novel p53-independent activity of PRIMA-1 Met to inhibit MEK and suppress colorectal cancer growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · cited 1×
“Moreover, mutant p53 acquires gain-of-function to promote malignant phenotypes of cancer [25].”
BackgroundTargeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 2×
“PRIMA-1 is one of chemical compounds originally identified by screening a library of low-molecularweight compounds [10].”
BackgroundTP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect
Zhang, C., Lin, M., Wu, R., Wang, X., Yang, B., Levine, A. J., Hu, W., & Feng, Z. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113884108 · Cited by 431
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
Medico, E., Russo, M., Picco, G., Cancelliere, C., Valtorta, E., Corti, G., Buscarino, M., Isella, C., Lamba, S., Martinoglio, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms8002 · Cited by 302
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230 · cited 1×
“So far, no K-Ras mutant inhibitors are available for clinical practice [19, 20].”
BackgroundEbi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57909 · Cited by 210
Peng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.417 · Cited by 170
PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
Tessoulin, B., Descamps, G., Moreau, P., Maïga, S., Lodé, L., Godon, C., Marionneau-Lambot, S., Oullier, T., Le Gouill, S., Amiot, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548800 · Cited by 166
PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
(2008) · PubMed Central · doi:10.3233/clo-2008-0440 · Cited by 68
Cited by
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Perdrix, A., Najem, A., Saussez, S., Awada, A., Journe, F., Ghanem, G., & Krayem, M. (2017) · Cancers · doi:10.3390/cancers9120172 · Cited by 126
“Indeed, the role of the reactive oxygen species (ROS) in the PRIMA-1/APR-246 anti-tumor activity appeared since 2009 [20], with a global consensus between the authors: an increase of the amount of ROS [20,34,37, 52,53,56,59,62] and a decrease of glutathione cellular content [37,40,53,62] have been widely reported unde…”
BackgroundInfluentialPotential and mechanism of mebendazole for treatment and maintenance of ovarian cancer
Elayapillai, S., Ramraj, S., Benbrook, D. M., Bieniasz, M., Wang, L., Pathuri, G., Isingizwe, Z. R., Kennedy, A. L., Zhao, Y. D., Lightfoot, S., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.10.010 · Cited by 50
Metadata
- Authors
- Lu, T., Zou, Y., Xu, G., Potter, J. A., Taylor, G. L., Duan, Q., Yang, Q., Xiong, H., Qiu, H., Ye, D., Zhang, P., Yu, S., Yuan, X., Zhu, F., Wang, Y., & Xiong, H.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-10-27
- Volume
- 7
- Issue
- 50
- Pages
- 83017-83030
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2543654328
- Cited by
- 22
- References
- 12
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.